Merck KGaA (MRK) Given a €115.00 Price Target at UBS

UBS set a €115.00 ($141.98) target price on Merck KGaA (FRA:MRK) in a report released on Wednesday, March 14th, www.boersen-zeitung.de reports. The firm currently has a buy rating on the healthcare company’s stock.

Several other research firms have also commented on MRK. JPMorgan Chase set a €95.00 ($117.28) price objective on Merck KGaA and gave the stock a neutral rating in a research note on Wednesday, January 10th. Sanford C. Bernstein set a €115.00 ($141.98) price objective on Merck KGaA and gave the stock a buy rating in a research note on Wednesday, January 17th. Kepler Capital Markets set a €115.00 ($141.98) price target on Merck KGaA and gave the stock a buy rating in a research note on Wednesday, January 17th. Warburg Research set a €115.00 ($141.98) price target on Merck KGaA and gave the stock a buy rating in a research note on Wednesday, December 13th. Finally, DZ Bank reiterated a neutral rating on shares of Merck KGaA in a research note on Tuesday, November 14th. Twelve investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Merck KGaA currently has an average rating of Hold and a consensus target price of €100.32 ($123.85).

How to Become a New Pot Stock Millionaire

Shares of FRA:MRK traded down €0.20 ($0.25) during midday trading on Wednesday, hitting €80.50 ($99.38). The company had a trading volume of 476,617 shares. Merck KGaA has a 12-month low of €76.60 ($94.57) and a 12-month high of €115.00 ($141.98).

ILLEGAL ACTIVITY NOTICE: “Merck KGaA (MRK) Given a €115.00 Price Target at UBS” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/07/merck-kgaa-mrk-pt-set-at-115-00-by-ubs-group.html.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply